Synthesis and biological activity of trans-2,3-dihydroraloxifene

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 8, 1999, Pages 1137-1140

  Schmid, Christopher R ^a   Glasebrook, Andrew L ^a   Misner, Jerry W ^a   Stephenson, Gregory A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRORALOXIFENE; ANTIESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERIVATIZATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULAR MODEL; REACTION ANALYSIS; RECEPTOR AFFINITY; STEREOCHEMISTRY;

BINDING, COMPETITIVE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; MODELS, MOLECULAR; PIPERIDINES; RALOXIFENE; TUMOR CELLS, CULTURED;

EID: 0033583542     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00145-6     Document Type: Article

References (27)

1. Marketed as Evista® (Raloxifene Hydrochloride 60 mg) (a) Jones, C. D.; Jevikar, M. G.; Pike, A. J.; Peters, M.K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. J. Med. Chem. 1984, 27, 1057.
2. (b) Delmas, P. E.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux, A-C.; Shah, A. S.; Huster, W. J.; Draper, M.; Christiansen, C. N. Engl. J. Med. 1997, 337, 1641.
3. (c) Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. J. Bone Mineral Res. 1996, 11, 835.
4. (a) Grese, T. A.; Dodge, J. A. Curr. Pharm. Des. 1998, 4, 71.
5. (b) Bryant, H. U.; Dere, W. H. Proc. Soc. Exp. Biol. Med. 1998, 217, 45.
6. (c) Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Proc. Nat. Acad. Sci. U.S.A., 1997, 94, 14105.
7. (d) Grese, T. A.; Dodge, J. A. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic: New York, 1996; Vol. 31, pp 181-190.
8. (e) Kauffman, R. F.; Bryant, H. U. Drug News Perspect. 1995, 8, 531.
9. (f) Evans, G. I.; Turner, R. T. Bone 1995, 17, 1818.
10. (a) Grese, T. A.; Pennington, L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 1998, 41, 1272.
11. (b) Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. J. Med. Chem. 1997, 40, 1407.
12. (c) Grese, T. A.; Cho, S.; Finley, D. A.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W. III; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 1997, 40, 146.
13. (d) Martin, M. J.; Grese, T. A.; Glasebrook, A. L.; Matsumoto, K.; Pennington, L. D.; Phillips, D. L.; Short, L. L. Bioorg. Med. Chem. Lett. 1997, 7, 887.
14. (e) Grese, T. A.; Cho, S.; Bryant, J. U.; Cole, H. W.; Glasebrook, A. L.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L. Bioorg. Med. Chem. Lett. 1996, 6, 201.
15. (e) Cameron, K. O.; Da Silva-Jardine, P.; Larson, E. R.; Hauske, J. R.; Rosati, R. L. PCT Int'l Appl. WO9510513; Chem. Abstr. 123:143630.
16. (a) Conley, R. A.; Heindel, N. D. J. Org. Chem. 1976, 41, 3743.
17. (b) Camoutsis, C.; Catsoulacos, P.; Salem, G.; Terzis. A.; Fillippakis, S. E. J. Heterocycl. Chem. 1981, 18, 1405.
18. (c) Al Nakib, T.; Looney, M. J.; Burke, M. L. Eur. J. Med. Chem. 1992, 27, 971.
19. (a) Godfrey, A. G. U.S. Patent 5,466,810, 1995; Chem. Abstr. 1996, 124, 175813.
20. (b) Godfrey, A. G. U.S. Patent 5,420,349, 1995; Chem. Abstr. 1995, 123, 111843.
21. Ablenas, F. J.; George, B. E.; Maleki, M.; Jain, R.; Hopkinson, A. C.; Lee-Ruff, E. Can. J. Chem. 1987, 65, 1800.
22. Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815.
23. The majority of 9 was found in the initial difference Fourier map and refined smoothly. Coordinates for the missing ethylpiperidinyl portion of the molecule were generated by molecular modeling of the disordered region.
24. (a) Node, M.; Nishide, K.; Fuji, K.; Fujita, E. J. Org. Chem. 1980, 45, 4275.
25. (b) Peters, M. K. U.S. Patent 4,380,635, 1983; Chem. Abstr. 1983, 99, 22309.
26. Thompson, E. W.; Reich, R.; Shima, T. B.; Albini, A.; Graff, J.; Martin, G. R.; Dickson, R. B.; Lippman, M. E. Cancer Res. 1988, 48, 6764. RBA values represent an average of two or more determinations and are accurate to ±10%.
27. Jordan, V. C.A. Br. J. Pharmacol. 1993, 110, 507.